• br Conflict of interest statement br Acknowledgements

  2022-10-01

  

  Conflict of interest statement Acknowledgements RF is supported by Pancreatic Cancer Research Fund (grant to MF); MF is supported by Prostate Cancer UK (PG12-23 and PG13-029). Background Lysophosphatidylinositol Molecular species and the biosynthesis of phosphatidylinositol, the precu

• br Introduction Activation of the

  2022-10-01

  

  Introduction Activation of the lipid sensing receptor, GPR55, by lysophosphatidyl inositol (LPI) has been well documented, and implicated in endocannabinoid signaling [1]. Intracellular events resulting from GPR55 activation include; enhanced β-arrestin activity, calcium mobilization and ERK1/2 p

• Foreign polypeptide antigens can be incorporated into VLPs t

  2022-10-01

  

  Foreign polypeptide antigens can be incorporated into VLPs to create “chimeric” structures, either as fusions to either end of the VLP capsid (coat) protein (CP) or as additions to well-presented loops [18]. This kind of direct fusion to the coat is usually good for small peptides, however, larger p

• Compared to previously reported atypical

  2022-09-30

  

  Compared to previously reported atypical N-glycosites that were identified based on the deamidation of asparagine residues after PNGase F treatment [106], [107], these two studies further validated the identified atypical motif glycosites by directly identifying their intact glycopeptides. Since the

• br Xenobiotics and the Glucocorticoid

  2022-09-30

  

  Xenobiotics and the Glucocorticoid Receptor Conclusion Transparency document Acknowledgements The author wishes to thank Professor Wilhelm Engström from the Swedish University of Agricultural Sciences (Department of Biomedical Sciences and Veterinary Public Health) for his proof reading

• Decreases in LS mean h WMG versus placebo were

  2022-09-30

  

  Decreases in LS mean 24-h WMG versus placebo were observed with both the 10mg q.d. a.m. (−18.8mg/dL) and 6mg q.d. p.m. (−25.0mg/dL) MK-3577 ‘partial blockade’ regimens, but was not assessed for the 25mg b.i.d regimen. Decreases in FPG versus placebo were observed for both the 10mg q.d. a.m. (−7.2mg/

• Data were collected using a Powerlab

  2022-09-30

  

  Data were collected using a Powerlab and Chart 5 software (ADInstruments, Bella Vista, NSW, Australia) and were analysed using GraphPad Prism 5 (GraphPad Software, San Diego, CA). Responses to ghrelin receptor agonists in phenylephrine, methoxamine, endothelin-1, U46619 and 60mM [K+] contracted vess

• Most of the tumors showed relatively higher

  2022-09-30

  

  Most of the tumors showed relatively higher GalR1 mRNA levels than the controls (Fig. 1a, Table 3). However one patient with the lower GalR1 mRNA levels (#12) had, in fact, relatively lower levels of transcript for galanin and the other galanin receptors. Patient #10 and 4 who were also expressing l

• Introduction galactosidase d galactoside galactohydrolase or

  2022-09-30

  

  Introduction β-galactosidase (β-d-galactoside galactohydrolase or lactase; EC 3.2.1.23) is an important type of glycoside hydrolase that can catalyze the conversion of lactose to Fmoc-Hyp-OH mg and galactose. Furthermore, it can also catalyze transglycosylation reactions, which are usually used fo

• Because FPR is expressed in VSMCs and

  2022-09-30

  

  Because FPR-1 is expressed in VSMCs and its role in non-hematopoietic cells is still unclear, we questioned whether FPR-1 would have physiological relevance for vascular behavior, in the same way as it does in neutrophils (Ca2+ homeostasis and LB42708 polymerization). First, we tested if FPR-1 is i

• Receptor interactions and binding mode of

  2022-09-30

  

  Receptor interactions and binding mode of in hGPR40 were determined by docking studies. The compound was docked in the rebuilt co-crystal structure of hGPR40 (PDB ID: ) using MOE for loop modeling and energy minimization and Glide for molecular docking. The docking site used for the docking simulat

• br Acknowledgements We thank Kathy Spindler for helpful

  2022-09-30

  

  Acknowledgements We thank Kathy Spindler for helpful review of the manuscript. Expert technical assistance from Joel Whitfield in the University of Michigan Cancer Center Immunology Core is greatly appreciated. This research was supported by the American Heart Association (16GRNT30250013) and by

• Previous study demonstrated that Hcy elevated

  2022-09-29

  

  Previous study demonstrated that Hcy elevated organ culture-induced up-regulation of ETB receptor in VSMCs (Chen et al., 2016a; Chen et al., 2016b). Many signaling pathways were involved in Hcy-induced up-regulation of ETB receptor in VSMCs, such as ERK1/2/NF-κB signaling pathway, Sirt1/NF-κB signal

• Despite the importance of intratumor phenotypic heterogeneit

  2022-09-29

  

  Despite the importance of intratumor phenotypic heterogeneity for tumor progression and therapy resistance (Marusyk et al., 2012, Marusyk and Polyak, 2010), our understanding of regulators of this process and our ability to modulate them are very limited. Recent advances in genomic sequencing and si

• br Histamine H R The cloning of the H

  2022-09-29

  

  Histamine H4R The cloning of the H3R (Lovenberg et al., 1999) provided a template for the search of other cathepsin inhibitor receptors, and resulted in the most recent discovery of histamine H4R. This concluded with six independent groups that have reported the cloning of the H4R (Leurs et al.,

16834 records 419/1123 page Previous Next First page 上5页 416417418419420 下5页 Last page